Brooks Ensign
VP, Controller @Aptose Biosciences, Inc
Signup · Get unlimited contacts
WORK HISTORY
VP, Controller @Aptose Biosciences, Inc
San Diego, CA, US
VP, ControllerOncology drug development, clinical trials Equity Financings: S-1 in January 2024:$9 million; Strategic private investor:$7 million, ATM:$2 million, Committed Equity Facility:$2 millionAptose Biosciences (Nasdaq: APTO, TSX: APS) is a publicly traded, clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer,Lead multinational accounting team. Implemented Active Disclosure for 10-K, 10-Q filings, recent S-1 filing. Public Equity Financings: S-1 (three S-1s), S-3, ATM, Committed Equity Facility (CEF). Implemented FloQast.
EDUCATION
University of California San Diego
Accounting Certificate ( All CPA coursework completed) and AIPB Bookkeeper certification, Accounting
Harvard Business School and Harvard College
MBA
National University
Master's degree, Accounting
ABOUT BROOKS ENSIGN
Phone: 31••••••60; email: b••••••••@gmail.com Harvard MBA with second Master\'s in Accounting (all CPA-required courses completed) Public Company VP, Corporate Controller,(Acting CFO for IPO Preparations with Silvaco in 2022) Public Equity Financings: Three recent S-1 filings, S-3 filing, ATM, Committed Equity Facility (CEF), PIPE AI, Artificial Intelligence: Nervana Systems, Intel, RapidAI, other AI companies * IPO Preparations, Recent S-1 Filing (Workiva, with rapid implementation)* Recent 10-K and 10-Q (Active Disclosure with rapid implementation)* MBA, M.Acc.( Masters in Accounting, all CPA courses completed)* UCLA: Teaching Advanced Corporate Finance for UCLA Extension ( Advanced Applications of Managerial Finance ) Winter terms, 2023 and 2024 * UCSD Professional Certificates: Biotechnology and Drug Development (20+ biotech courses,(completed the program after helping to design it), Accounting and Bookkeeping * Strategic Finance: M&A, FP & A, Corporate Development * IPO Preparations for Technology and Life Sciences companies, RECENT S-1 preparation * Multiple recent PCAOB, Big Four (public company, SEC standard) audits, ASC 606, ASC 842, ASC 805,* SEC Reporting (> 10 companies): S-1, S-3, 10-K, 10-Q, Restatements, Proxy, Workiva, AD2, etc.* Biotech / Pharmaceutical experience with multiple companies: Aptose, Sunesis Pharmaceuticals (oncology), Valeant (Bausch Health), Halozyme, ISTA Pharmaceuticals, Jaguar Health, Tricida, Amylin, Advanced Biologics, Advanced Tissue Sciences, AVIVA Biosciences, etc.* Artificial Intelligence, Semiconductor experience: RapidAI, Silvaco, Intel / Nervana Systems (Deep Learning AI), and other companies (clients)* ASC 842 Lease implementation for multiple foreign and domestic leases * Netsuite, Intacct, Microsoft Dynamics, Workiva W Desk, Workiva Capital Markets ( S-1), Shareworks, Equity Edge, Adaptive Disclosure, Carta, Quickbooks, Blackline, FloQast, OneStream, Tableau, Power BI, Adaptive Insights, MerrillBridge, etc.* Corporate Finance Institute Ensign Ensign, Navy Combat Veteran (USS BUNKER HILL, CG-52)
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.